

Government of the People's Republic of Bangladesh
Directorate General of Drug Administration
Ministry of Health and Family Welfare
Aushad Bhaban, Mohakhali, Dhaka-1212
www.dgda.gov.bd

Memo No.: DGDA /Admin/40-1/08 (Part-1)/ 529

Date:25...../.....05...../2023


Subject: Piloting of Online Adverse Events Reporting Tool (PViMS).

We are pleased to announce the launching and piloting of online Adverse Event Reporting Tool of DGDA to be used by Marketing Authorization Holders (MAHs). This system is in line with the recommendations of WHO assessors as per assessment of the WHO Global Benchmarking Tool.

The online adverse event reporting tool has been developed by DGDA with the technical assistance of USAID MTaPS program and is now live on the DGDA website (pv.dgda.gov.bd). A comprehensive training program and User Acceptance Test (UAT) was conducted at DGDA for Marketing Authorization Holders (MAHs) on May 18, 2023.

From 27 May 2023, and onwards, the listed Marketing Authorization Holders (MAHs) should use the tool for next one month for reporting adverse events and provide input for further improvement, if any. Upon addressing feedback, the tool will be publicly available for all. For any assistance related to software operation, DGDA Pharmacovigilance Cell is available to provide support. To aid in software use, a user manual is available online (www.dgda.gov.bd) for all users.

We are confident that the tool will enhance the efficiency and quality of the adverse event reporting, resulting in a more streamlined and effective pharmacovigilance system. We appreciate your cooperation and look forward to your successful use of the system.


Major General Mohammad Yousuf
Director General
Directorate General of Drug Administration
Phone: 022222-80803, Email: dgda.gov@gmail.com
25 MAY 2023

Distribution:


1. Managing Director, Beximco Pharmaceuticals Ltd.
2. Managing Director, Incepta Pharmaceuticals Ltd.
3. Managing Director, Novartis (BD) Limited
4. Managing Director, Roache Bangladesh Limited
5. Managing Director, Nuvista Pharma Limited

Memo No.: DGDA /Admin/40-1/08 (Part-1)/ 529

Date:25...../.....05...../2023

Copy for information -

1. Secretary, Health Services Division (HSD), MoHFW, Dhaka
2. President/Secretary, Bangladesh Association of Pharmaceutical Industries (BAPI), Dhaka
3. Director, Administration, DGDA
4. Head, Marketing Authorization (MA), DGDA
5. Head, Pharmacovigilance, DGDA
6. Office Copy


Director General
Directorate General of Drug Administration
25 MAY 2023